tert-butyl 3-(2-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate

Catalog No.: 
ACACJK070
CAS No.: 
-
Molecular Formula: 
C25H32N4O6
Molecular Weight: 
484.55
tert-butyl 3-(2-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$358.00In stock1 week
250mg95%$715.00In stock1 week
1g95%$1660.00In stock1 week

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl 3-(2-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate
IUPAC Nametert-butyl 3-(2-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate
Molecular FormulaC25H32N4O6
Molecular Weight484.55
SMILESCC(C)(C)OC(=O)N1CCC(CC(=O)NCC2=CC=C3C(=O)N(C4CCC(=O)NC4=O)CC3=C2)C1
InChI KeyXZGPUDBCJXPJBI-UHFFFAOYSA-N

Synthetic Route by SureRoute

1. ACACJK070 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACQRIC031 route compound structure diagram
    ACQRIC031175526-97-3In Stock
  2. Plus
  3. ACYFSO975 route compound structure diagram
    ACYFSO9751158264-69-7In Stock
  4. Then
  5. ACACJK070 route product structure diagram
    ACACJK070-In Stock
Inquiry

2. ACACJK070 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACYFSO975 route compound structure diagram
    ACYFSO9751158264-69-7In Stock
  4. Then
  5. ACACJK070 route product structure diagram
    ACACJK070-In Stock
Inquiry

3. ACACJK070 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACACJK070 route product structure diagram
    ACACJK070-In Stock
Inquiry

Comments (0)